NDAINTRAVENOUSSOLUTION
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GALLIUM GA 68 GOZETOTIDE (gallium ga-68 gozetotide) by Angeles Therapeutics is positron emitting activity [moa]. First approved in 2020.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GALLIUM GA-68 GOZETOTIDE is a positron-emitting radioactive diagnostic agent administered intravenously as a solution. It functions as a diagnostic imaging agent that leverages positron emission to detect and localize disease. The product is used in nuclear medicine imaging to identify specific disease states in patient populations.
Peak
Product is at peak revenue stage with moderate competitive intensity (30/100); diagnostic radiopharmaceuticals typically operate with smaller commercial teams focused on hospital nuclear medicine departments and radiology partnerships.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GALLIUM GA-68 GOZETOTIDE positions you in the specialized diagnostic imaging/radiopharmaceutical space, a niche but strategically important segment of pharmaceutical oncology and nuclear medicine. Roles emphasize deep clinical relationships with nuclear medicine physicians, radiologists, and hospital imaging centers, combined with strong regulatory and medical affairs acumen in the complex radiopharmaceutical approval and commercialization landscape.
Medical Science Liaison
Worked on GALLIUM GA 68 GOZETOTIDE at Angeles Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.